How one medtech startup and its preclinical research partner overcame pandemic-related obstacles to continue its medical device research project. Prior to COVID-19, VentureMed was on a roll. The Minneapolis, MN-based company’s first-generation Flex Vessel Prep System had demonstrated promising clinical performance following FDA clearance and the company was preparing to introduce an improved second-generation device. […]
Category Archives: Coverage
News coverage
Cardiovascular News: FLEX Vessel Prep™ System Data Presented During Leipzig Interventional Course (LINC) 2021
Trio of studies demonstrate that FLEX Vessel Prep System safely and effectively modifies obstructive plaque to facilitate delivery of definitive therapies MINNEAPOLIS, Jan. 27, 2021 — VentureMed Group, Inc. (VentureMed), a privately-held medical device innovator, announced today that data from three studies evaluating the use of its FLEX Vessel Prep (VP) System were presented during […]
Endovascular Today: CBSET Preclinical Study Shows Balloon-Based Drug Delivery Is Critically Dependent on Coating Micromorphology
September 30, 2020—CBSET Inc., a not-for-profit translational research institute, announced the publication of a preclinical study, “Balloon-based drug coating delivery to the artery wall is dictated by coating micro-morphology and angioplasty pressure gradients,” by Abraham R. Tzafriri, PhD, et al, online ahead of print in the Journal of Biomaterials.
Medical Alley: COVID-19 and Quarantine – Can’t keep a medical device start-up down
COVID-19 has significantly and adversely affected preclinical research and clinical trials across the universe of life science companies as a result of the suspension of elective procedures in the U.S. and globally, as well as the challenges posed by travel bans, the furlough of or requirement that clinical study personnel work remotely, restrictions on access […]
Endovascular Today: Computational Model Suggests a New Paradigm for Accelerated Treatment Optimization With Paclitaxel Devices
August 28, 2019—CBSET announced that its scientists have published data and analyses that provide critical insights into the interplay between target anatomy and device attributes in determining balloon- and stent-based paclitaxel retention in healthy and diseased arteries. According to CBSET, these findings may transform the understanding of the safety and efficacy of paclitaxel-coated devices used […]
Endovascular Today: Lesion Preparation Using Diamondback 360 OAS Shown to Enhance Paclitaxel Distribution in Calcified PAD
September 11, 2017—CBSET announced that its scientists have published data and analyses regarding the barrier effects of calcified plaque on drug delivery and the treatment success of adjunctive lesion preparation therapy in the treatment of peripheral atherosclerosis. CBSET is a not-for-profit preclinical research institute dedicated to translational research, education, and advancement of medical technologies. According […]
Endovascular Today: Preclinical Study Evaluates Primary Lesion Treatment With CSI’s Orbital Atherectomy System Before Drug Delivery in Calcified PAD
May 20, 2015—CBSET, a preclinical biomedical research institute, announced findings from a cadaver study suggesting that modification of atherosclerotic plaque with the Diamondback 360 orbital atherectomy system (Cardiovascular Systems, Inc. [CSI]) improved drug uptake in calcified peripheral lesions. Gunnar Tepe, MD, from RoMed Hospital in Rosenheim, Germany, stated in CBSET’s announcement, “This preclinical study could have a significant […]
Endovascular Today: Study Suggests That Local Tissue Anatomy May Explain Variable Patient Responses to RDN Therapy
May 4, 2015—CBSET, a not-for-profit preclinical research institute, announced that its scientists have published data and analyses that provide critical insights into the predictability, variability, and treatment success of catheter-based renal denervation (RDN) therapy. These data suggest that new, optimal alternative devices compared to first-generation RDN systems may enhance or assure efficacy, stated CBSET. The […]
DAIC: CBSET Scientists Indicate Preclinical Research is Critical to the Future of Renal Denervation
March 27, 2014 — Scientists at CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education and advancement of medical technologies, are reminding thought leaders in renal denervation that there is a seminal experimental and computational template for the more rational, comprehensive preclinical evaluation and optimization of renal denervation devices that can be utilized […]
DAIC: CBSET Presents Preclinical Development Data on Renal Denervation Devices
October 28, 2013 — CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education and advancement of medical technologies, will present data from the podium at the Transcatheter Cardiovascular Therapeutics annual scientific meeting (TCT 2013) that provides a seminal experimental and computational template for a more rational, comprehensive preclinical evaluation and optimization of renal […]